Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced company highlights and financial results for the first quarter ended March 31, 2014.
“Since the beginning of 2014, we have made solid progress in developing improved treatment options for cancer patients with our proprietary drug candidates and expanding our integrated Rx/Dx discovery and development capabilities,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta.
Help employers find you! Check out all the jobs and post your resume.
